Clearmind Medicine Shares On The Move With Cash Question Looming
Clearmind Medicine shares rose 1.7% to $2.96 in midday Nasdaq trading after announcing a $1.5 million convertible-note deal. The company faces funding concerns, as noted in its latest annual filing. A webinar update on its CMND-100 alcohol-use-disorder trial is set for June 10. Clearmind remains in the clinical stage with no product revenue.